ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1075

Diagnostic Utility of Myositis Antibodies in HyperCKemia: A University Affiliated Single Center Retrospective Study

Sandeepkumar Gupta1, Debendra Pattanaik2, Tulio Bertorini2 and Amado Afreire3, 1Medical College Of Georgia at Augusta University Medical Center, Augusta, GA, 2University of Tennessee Health Science Center, Memphis, TN, 3University of Tennessee Health Science Cente, Memphis, TN

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), Myositis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: Muscle Biology, Myositis & Myopathies Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Myositis specific and associated autoantibodies are now being used more frequently in the diagnosis of idiopathic inflammatory myositis. However there is a no study looking at the utility of antibody testing in subjects presenting with HyperCKemia during routine clinical practice. We aimed to determine the usefulness of antibody testing in subjects with both symptomatic and asymptomatic hyperCKemia referred to a university affiliated practice.

Methods: This was a retrospective chart review of electronic health records of subjects in whom antibody testing was performed between January 2013 till December 2018. The autoantibody testing were performed using myomarker panel 3® (Anti-Jo-1 Ab, Anti-Mi-2 Ab, Anti-PL-12 Ab, Anti-PL-7 Ab, Anti-EJ Ab, Anti-OJ Ab, Anti-SRP Ab, Anti-Ku Ab, Anti-U2 RNP, Anti-PM/Scl-100 Ab, Anti-MDA5 Ab, Anti-NXP2 Ab, Anti-TIF-1γ Ab, Anti-SSA 52 kD IgG Ab, Anti-U1 RNP Ab, Anti-Fibrillarin U3 RNP Ab), [RDL Reference Laboratory, Los Angeles, CA], Anti-cN-1A (NT5c1A)and Anti-HMGCR Ab IgG . Baseline demographics, reason for referral, presenting symptoms, muscle enzymes (CPK, Aldolase, ALT, AST), autoantibody results, electromyography and nerve conduction studies (EMG & NCS), muscle biopsies and final clinical diagnosis were extracted from the records.

Only HyperCKemia with and without symptoms were considered for the study. We used Stat view version 5.01 (SAS Institute Inc. Cary, NC) for analysis

Results: There were 138 subjects for whom antibody testing were performed. 47 subjects met our inclusion criteria. 9 subjects were excluded from final analysis as their final diagnosis was not classified. 38 subjects included in final analysis. Baseline demographics, presenting symptoms and muscle enzyme levels are presented in table 1. Results of EMG & NCS, myositis antibody and final clinical diagnosis details are presented in table 2. The relationship between CPK, final diagnosis and myositis antibodies are shown in Figure 1.  Subjects with moderate elevation of CPK and positive antibody are more likely to have polymyositis. Subjects with mild elevation of CPK and positive antibody are more likely to have inclusion body myositis. Negative antibody subjects are more likely to be diagnosed with idiopathic hyperCKemia and metabolic myopathy. 

Antibody positive was statistically associated with polymyositis, inclusion body myositis with a chi square of 25.94 with p value 0.002 with 9 degree of freedom.

Antibody positivity was statistically associated with inflammatory myositis on muscle biopsy with a chi square of 16.37 p value 0.01 with 6 degree of freedom.

Metabolic myopathy will likely have negative myositis antibody test.

Conclusion: Subjects presenting with asymptomatic or symptomatic hyperCKemia and having positive antibody, are more likely to have positive muscle biopsy and final diagnosis of inflammatory myositis.  Therefore, performing initial antibody testing in such cases would help clinicians in pursuing these cases with EMG & muscle biopsy. 

Table 1. Baseline Characteristics of study population(N = 47)

Table 2. Muscle biopsy, EMG & NCS, Myositis antibody and Final clinical diagnosis

Figure 1: Box plot analysis of CPK, final diagnosis and antibody status


Disclosure: S. Gupta, None; D. Pattanaik, None; T. Bertorini, None; A. Afreire, None.

To cite this abstract in AMA style:

Gupta S, Pattanaik D, Bertorini T, Afreire A. Diagnostic Utility of Myositis Antibodies in HyperCKemia: A University Affiliated Single Center Retrospective Study [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/diagnostic-utility-of-myositis-antibodies-in-hyperckemia-a-university-affiliated-single-center-retrospective-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/diagnostic-utility-of-myositis-antibodies-in-hyperckemia-a-university-affiliated-single-center-retrospective-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology